Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Janus kinases (JAKs) are a family of intracellular, non-receptor tyrosine kinases that play a central role in transducing cytokine-mediated signals via the JAK-STAT pathway. They are essential for cell growth, survival, development, and differentiation, especially within immune and hematopoietic cells. There are four members in the mammalian JAK family: JAK1, JAK2, JAK3, and TYK2. Upon cytokine binding to receptors, JAKs are activated, leading to STAT phosphorylation, dimerization, and translocation to the nucleus to regulate gene transcription. They are vital targets for therapeutic intervention across multiple disease areas.
JAK inhibitors block the activity of Janus kinases, preventing the phosphorylation and activation of STAT proteins, thereby inhibiting cytokine-mediated signaling and reducing inflammation and immune responses.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Janus Kinase (JAK).